Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NSE - Delayed Quote INR

Mangalam Drugs & Organics Limited (MANGALAM.NS)

Compare
79.00
+4.39
+(5.88%)
At close: April 11 at 3:29:38 PM GMT+5:30

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
NameTitlePayExercisedYear Born
Mr. Govardhan Murlidhar Dhoot Chairman & MD 2.01M -- 1953
Dr. Kamal Ishvarlal Vashi President -- -- 1980
Ms. Krishnapriya Nawal Chief Operating Officer -- -- 1985
Mr. Brijmohan Murlidhar Dhoot Whole-Time Director 613k -- 1951
Ms. Anuradha Pandey Company Secretary & Compliance Officer -- -- 1993
Mr. Yaduraj Dhoot Head of Purchase -- -- 2000
Ms. Mansi Sidhinath Pathak Senior Manager -- -- 1979
Mr. Rakesh Sakikram Srivastava General Manager -- -- 1974
Dr. Bhanvesh Dinesh Naik General Manager -- -- 1979

Mangalam Drugs & Organics Limited

Rupam Building
3rd Floor 239, P D’ Mello Road Near GPO
Mumbai, 400001
India
91 22 6261 6200 https://www.mangalamdrugs.com
Sector: 
Healthcare
Full Time Employees: 
432

Description

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers API products, including acyclovir, amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; and ortho phenoxy methane sulfonanilide, tenofovir alafenamide base, and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol; bictegravir Na, aripiprazole, risperidone, olanzapine, and etodolac; and develops tafenoquine succinate and pretomanid. Further, it manufactures organic and inorganic chemicals, and heavy chemicals. The company was incorporated in 1972 and is based in Mumbai, India.

Corporate Governance

Mangalam Drugs & Organics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 13, 2025 at 10:59 AM UTC

Mangalam Drugs & Organics Limited Earnings Date

Recent Events

December 21, 2017 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.